• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Cerus Corp

NASDAQ:CERS

$3.49 -$0.06 (-1.69%)

REAL-TIME: Last trade at

NASDAQ Changes Up Biotech Index Members & Weightings

NASDAQ Biotechnology Index - semi-annual changes

Cerus Corporation Reports First Quarter 2012 Results

Cerus Corp (CERS) Misses Q1 EPS by 8c; Guides Below

Cerus sees FY12 revenue $34M-$36M, consensus $37.29M.

Cerus reports Q1 EPS (17c), consensus (8c)

Cerus Corporation Reports First Quarter 2012 Results

Cerus, the University Hospitals of Geneva, and the Transfusion Service of the Swiss Red Cross Intend to Collaborate on Whole Blood Pathogen Inactivation for Africa

Cerus, the University Hospitals of Geneva, and the Transfusion Service of the Swiss Red Cross Intend to Collaborate on Whole Blood Pathogen Inactivation for Africa

Cerus and New York Blood Center to Collaborate on Development of Novel Red Blood Cell Biologic Product with Improved Uniformity

Cerus, NY Blood Center announce research collaboration

Cerus and New York Blood Center to Collaborate on Development of Novel Red Blood Cell Biologic Product with Improved Uniformity

Cerus Announces First INTERCEPT Platelet System Customer in Austria

Cerus announces first INTERCEPT platelet system customer in Austria

Cerus Announces First INTERCEPT Platelet System Customer in Austria

Cantor Fitzgerald Starts Cerus (CERS) at Buy; Potential Game-Changer in Blood

Cerus initiated with a Buy at Cantor

Cerus to Release First Quarter 2012 Results on May 1, 2012

Cerus to Release First Quarter 2012 Results on May 1, 2012

My Favorite Stock Idea For The Next Decade

Cerus Announces New Supply Agreement with Largest Blood Service in Saudi Arabia

Polycom Cerus distributor in Saudi Arabia signs agreement hospital

Cerus Announces New Supply Agreement with Largest Blood Service in Saudi Arabia

Cerus Submits Investigational Device Exemption (IDE) Supplement to FDA for Phase III INTERCEPT Red Blood Cell Study

Cerus submits IDe supplement to FDA for Phase III INTERCEPT study

Cerus Submits Investigational Device Exemption (IDE) Supplement to FDA for Phase III INTERCEPT Red Blood Cell Study

Cerus Spikes Higher, Spooks Shorts with Top-Line Surprise

Cerus Spikes Higher, Spooks Shorts with Top-Line Surprise

Cerus rises 12.5%

Cerus rises 8%

Baird Upgrades Cerus (CERS) to Outperform, Raises Price Target to $6

Cerus upgraded to Outperform from Neutral at RW Baird

Cerus Corp (CERS) Misses Q4 EPS by 7c

Cerus FY11-end cash of $25.8M compared to $30M FY10-end

Cerus sees FY12 product revenue $34M-$36M

Cerus Q4 gross margins 40% compared to 44% in 4Q10

Cerus reports Q4 EPS (16c) , consensus (9c)

Cerus Corporation Reports Fourth Quarter and Year-End 2011 Results

Cerus to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012

Cerus to Release Fourth Quarter and Year-End 2011 Results on February 28, 2012

See More Articles...